# Effect on Orencia (Abatacept) on the Apoptosis of T Cells, B Cells and APC Cells in Rheumatoid Arthritis

> **NCT01717846** · PHASE4 · WITHDRAWN · sponsor: **University of California, Los Angeles**

## Conditions studied

- Apoptotic DNA Damage
- Rheumatoid Arthritis
- T-cell Lymphocytosis

## Interventions

- **DRUG:** Group 1 or Orencia treated group
- **OTHER:** Group 2 (DMARDS treated group)

## Key facts

- **NCT ID:** NCT01717846
- **Lead sponsor:** University of California, Los Angeles
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-12
- **Primary completion:** 2013-11
- **Final completion:** 2014-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The PI has left UCLA and we do not plan to pursue this study.
- **Last updated:** 2016-05-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01717846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01717846, "Effect on Orencia (Abatacept) on the Apoptosis of T Cells, B Cells and APC Cells in Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01717846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*